Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) that has spread or cannot be surgically removed, confirmed through tissue testing or imaging.
• People who have already received one prior treatment for their advanced liver cancer, which must have included an anti-PD-L1 immunotherapy drug, and whose cancer has since progressed on that treatment.
• People aged 18 or older.
• People who are in relatively good general health, able to carry out normal daily activities with little or no limitation (this is measured using a standard scale called ECOG, score 0 or 1).
• People whose blood counts and organ function meet specific minimum levels — including white blood cell count, haemoglobin, platelets, and kidney function — as assessed by the trial site.
• People whose liver function falls within a specific range known as Child-Pugh class A or B7 (confirm with trial site).
• People who have at least one tumour that can be measured using standard imaging guidelines.
• People whose cancer shows up on a specific type of scan called a PSMA-PET scan, where the tumour absorbs more of the tracer than the surrounding liver tissue.
• People who are willing and able to give written informed consent to participate.
• People of childbearing potential who are using an appropriate method of contraception during the trial.

Who may not be able to join:

• People who are currently taking part in another clinical trial involving an experimental treatment.
• People who have received an experimental therapy within 4 weeks, or within 5 half-lives of that drug (whichever is shorter), before joining this trial.
• People who are still experiencing significant side effects (grade 3 or higher) from a previous cancer treatment.
• People who have previously been treated with a liver-directed radiation therapy called Y90 radioembolisation for their liver cancer.
• People who have had major surgery within 3 months before screening and have not sufficiently recovered.
• People who have another active cancer currently requiring treatment, with the exception of certain skin cancers or early-stage cervical cancer that has already been treated with curative intent.
• People who have untreated brain metastases (cancer that has spread to the brain) or cancer affecting the lining of the brain. People with previously treated brain metastases may be considered if the condition is stable, there are no signs of new or growing brain lesions, and they have not needed steroids for at least 7 days before starting trial treatment.
• People with serious uncontrolled health conditions such as active infection, uncontrolled heart failure, unstable chest pain, uncontrolled heart rhythm problems, or mental health or social circumstances that would make it difficult to follow the trial requirements.
• People with known psychiatric conditions or substance use disorders that the treating doctor believes would interfere with participation in the trial.
• People who are pregnant or breastfeeding, or who plan to conceive a child during the trial or within 7 months after the last dose (for females) or 14 weeks after the last dose (for males).
• People who have received a live vaccine within 30 days before the first dose of the trial treatment.
• People who have recently had bleeding from varicose veins in the digestive tract, other gastrointestinal bleeding, or who are considered at high risk of bleeding.

Important: Always verify eligibility with the trial site directly before applying.